Overview

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

Status:
Terminated

Trial end date:
2021-08-02

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess safety, tolerability and pharmacokinetics (PK) of oral UCB8600.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Biopharma SRL